{"entity":{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of Cabozantinib in renal cell carcinoma, run by Arcus Biosciences, Inc., now recruiting.","summary":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 3 interventional study registered as NCT07011719 by Arcus Biosciences, Inc., with 720 participants planned, started 2025-09-08 and due to reach its primary completion in 2028-04. Interventions recorded: Casdatifan, Cabozantinib, Placebo. Conditions listed: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07011719","url":"https://clinicaltrials.gov/study/NCT07011719"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc","clear-cell-rcc"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["cabozantinib"],"companies":["arcus-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07011719","phase":"3","setting":"A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","sponsor":"Arcus Biosciences, Inc.","participation":[{"nct":"NCT07011719","source":"https://clinicaltrials.gov/study/NCT07011719","fetchedAt":"2026-10-07T16:55:21.080Z","studySha256":"f7a0ab8086ffe834d607e0b4ee6c00ca552becbd4d6f2166142422f626cdfc30","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-29","leadSponsor":"Arcus Biosciences, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":720,"enrolmentType":"ESTIMATED","siteCount":183,"recruitingSiteCount":183,"countries":["Argentina","Australia","Canada","Czechia","France","Germany","Italy","Japan","Netherlands","New Zealand","Poland","Romania","Singapore","South Korea","Spain","United Kingdom","United States"]}],"started":"2025-09-08","startedType":"actual","enrolled":720,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07011719/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"}],"company":[{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/"}]}}